Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Beats Revenue Estimates

Core Insights - Intellia Therapeutics reported a quarterly loss of $0.99 per share, which was better than the Zacks Consensus Estimate of a loss of $1.03, and an improvement from a loss of $1.31 per share a year ago, resulting in an earnings surprise of +3.88% [1] - The company achieved revenues of $14.25 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 9.43%, and showing significant growth from $6.96 million in the same quarter last year [2] - Intellia Therapeutics has consistently surpassed consensus EPS estimates over the last four quarters, indicating a positive trend in performance [2] Company Performance - The stock has underperformed the market, losing about 2.5% since the beginning of the year, while the S&P 500 has gained 7.9% [3] - The current consensus EPS estimate for the upcoming quarter is -$1.03 on revenues of $13.39 million, and for the current fiscal year, it is -$4.24 on revenues of $57.71 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Intellia Therapeutics belongs, is currently ranked in the top 41% of over 250 Zacks industries, suggesting a favorable industry outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Intellia's stock performance [5][6]